Evidence map›Paper›PMID 36557259›Full record

ReviewMetabolites2022

Microbiome and Metabolome Insights into the Role of the Gastrointestinal-Brain Axis in Parkinson's and Alzheimer's Disease: Unveiling Potential Therapeutic Targets.

Helena U Zacharias, Christoph Kaleta, François Cossais, Eva Schaeffer, Henry Berndt, Lena Best, Thomas Dost, Svea Glüsing, Mathieu Groussin, Mathilde Poyet and 10 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Helena U ZachariasPeter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, 30625 Hannover, Germany.
Christoph KaletaResearch Group Medical Systems Biology, Institute for Experimental Medicine, Kiel University, 24105 Kiel, Germany.ORCID 0000-0001-8004-9514
François CossaisInstitute of Anatomy, Kiel University, 24118 Kiel, Germany.
Eva SchaefferDepartment of Neurology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
Henry BerndtResearch Group Comparative Immunobiology, Zoological Institute, Kiel University, 24118 Kiel, Germany.
Lena BestResearch Group Medical Systems Biology, Institute for Experimental Medicine, Kiel University, 24105 Kiel, Germany.ORCID 0000-0003-2772-153X
Thomas DostResearch Group Medical Systems Biology, Institute for Experimental Medicine, Kiel University, 24105 Kiel, Germany.
Svea GlüsingInstitute of Human Nutrition and Food Science, Food Technology, Kiel University, 24118 Kiel, Germany.
Mathieu GroussinInstitute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
Mathilde PoyetDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Sebastian HeinzelDepartment of Neurology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.ORCID 0000-0003-4516-0529
Corinna BangInstitute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
Leonard SiebertKiel Nano, Surface and Interface Science-KiNSIS, Kiel University, 24118 Kiel, Germany.ORCID 0000-0001-5316-7240
Tobias DemetrowitschInstitute of Human Nutrition and Food Science, Food Technology, Kiel University, 24118 Kiel, Germany.
Frank LeypoldtDepartment of Neurology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.ORCID 0000-0002-8972-515X
Rainer AdelungKiel Nano, Surface and Interface Science-KiNSIS, Kiel University, 24118 Kiel, Germany.ORCID 0000-0002-2617-678X
Thorsten BartschKiel Nano, Surface and Interface Science-KiNSIS, Kiel University, 24118 Kiel, Germany.ORCID 0000-0001-8387-5731
Anja Bosy-WestphalInstitute of Human Nutrition and Food Science, Kiel University, 24107 Kiel, Germany.
Karin SchwarzKiel Nano, Surface and Interface Science-KiNSIS, Kiel University, 24118 Kiel, Germany.ORCID 0000-0002-3943-0564
Daniela BergKiel Nano, Surface and Interface Science-KiNSIS, Kiel University, 24118 Kiel, Germany.
Christian-Albrechts-Universität zu Kiel · DEHochschule für Angewandte Wissenschaften Kiel · DEMassachusetts Institute of Technology · US

Funding

Deutsche Forschungsgemeinschaft CRC 1182 MetaorganismsDeutsche Forschungsgemeinschaft EXC 2167 "Precision Medicine in Chronic Inflammation"Deutsche Forschungsgemeinschaft KA 3541/18-1Else Kröner-Fresenius Stiftung: Interdisciplinary Else Kröner-Research College Kiel: The Role of the Gut-Brain-Axis in Neuroinflammation and Neurodegeneration Deutsche Forschungsgemeinschaft: Clinician Scientist Program in Evolutionary Medicine (CSEM)Federal Ministry of Education and Research 01ZX1912A
6 · The paper itself

Abstract

Neurodegenerative diseases such as Parkinson's (PD) and Alzheimer's disease (AD), the prevalence of which is rapidly rising due to an aging world population and westernization of lifestyles, are expected to put a strong socioeconomic burden on health systems worldwide. Clinical trials of therapies against PD and AD have only shown limited success so far. Therefore, research has extended its scope to a systems medicine point of view, with a particular focus on the gastrointestinal-brain axis as a potential main actor in disease development and progression. Microbiome and metabolome studies have already revealed important insights into disease mechanisms. Both the microbiome and metabolome can be easily manipulated by dietary and lifestyle interventions, and might thus offer novel, readily available therapeutic options to prevent the onset as well as the progression of PD and AD. This review summarizes our current knowledge on the interplay between microbiota, metabolites, and neurodegeneration along the gastrointestinal-brain axis. We further illustrate state-of-the art methods of microbiome and metabolome research as well as metabolic modeling that facilitate the identification of disease pathomechanisms. We conclude with therapeutic options to modulate microbiome composition to prevent or delay neurodegeneration and illustrate potential future research directions to fight PD and AD.

Indexed as

Alzheimer’s diseasegastrointestinal–brain axismetabolomicsmicrobiomemicrobiome modellingneurodegenerative diseasesParkinson’s diseasetherapeutic interventions

Identifiers

PMID36557259
PMCPMC9786685
OpenAlexW4311627874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.